Company news
Joincare Pharmaceutical Group Industry Co., Ltd. Class A (SSE:600380) news
Joincare Pharmaceutical Group Industry Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: "Joincare Pharmaceutical Group Industry Co.…
View Joincare Pharmaceutical Group Industry Co., Ltd. Class A →
Press releases & updates
"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Obtaining Notice of Approval for Drug Supplementary Application
September 29, 2026
"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
September 24, 2026
"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Election of Non-Independent Directors
September 18, 2026
"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Outline of the 2026 Semi-annual Performance Briefing
September 17, 2026
"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Change of Chairman and Adjustment of Members of Special Committees of the Board of Directors
September 11, 2026
"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on the Interim Profit Distribution Proposal for 2026
September 4, 2026
"Joincare Pharmaceutical Group Industry Co., Ltd."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 24, 2026
"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Progress in Providing Guarantee for Controlled Subsidiary
August 4, 2026
"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Progress in Providing Entrusted Loans to the Controlled Subsidiary Jiaozuo Jianfeng
July 31, 2026
"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Resolutions of the 3rd Holders' Meeting for the First Stock Ownership Plan
July 27, 2026
"Joincare Pharmaceutical Group Industry Co., Ltd."Announcement on Obtaining Drug Registration Certificate
July 23, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 17, 2026
Announcement on the Extension of the Duration of the Second Phase of the Company's Medium-to-Long-Term Business Partnership Shareholding Plan
June 1, 2026
Indicative Announcement on Convening the 2025 Annual General Meeting
May 22, 2026
Announcement on Outline of the Performance Briefing for 2025 and Q1 2026
May 15, 2026
Announcement on Progress and Completion of Transfer Registration Regarding the Holding Subsidiary Livzon Group's Public Tender Offer for Equity Interests of Vietnam IMP Company
May 11, 2026
Announcement on Progress in Providing Guarantee for Holding Subsidiary
May 8, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trials
May 6, 2026
Announcement on Progress in Holding Subsidiary Livzon Group Publicly Acquiring Equity of Vietnam IMP Company
April 29, 2026
Announcement on Resolutions of the 18th Meeting of the 9th Board of Directors
April 24, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of TSLP Monoclonal Antibody for New Indication
April 7, 2026
Announcement on Company Credit Financing and Providing Financing Guarantee for Subsidiaries
March 31, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of Brexpiprazole Microspheres for Injection
March 26, 2026
Announcement on Progress in Holding Subsidiary Livzon Group Planning to Publicly Acquire Equity of Vietnam IMP Company
March 6, 2026
Indicative Announcement on Extension of the Six-month Duration of Phase I of the Medium-and Long-term Business Partner Shareholding Plan
February 2, 2026
Announcement on Resolutions of the 16th Meeting of the 9th Board of Directors
January 30, 2026
Announcement on Appointment of Vice President
January 16, 2026
Indicative Announcement on Inclusion of Rekonkitta Monoclonal Antibody Injection into the Priority Review and Approval Program
January 7, 2026
Announcement on Subsidiary Obtaining PIC/S GMP Certification
December 30, 2025
Indicative Announcement on Acceptance of Marketing Authorization Application for Laikangchita Monoclonal Antibody Injection
December 24, 2025
Announcement on Obtaining Drug Registration Certificate for Maribavir Capsules (Yilikang®)
December 11, 2025
Announcement on the Inclusion of the Company’s Product in the National Medical Insurance Catalog
December 8, 2025
Indicative Announcement on Extension of the Six-month Duration of the Second Phase of the Medium-and Long-term Business Partner Shareholding Plan
December 5, 2025
Announcement on Outline of the Q3 2025 Performance Briefing
November 25, 2025
Announcement on Completion of Deregistration of the Special Account for Funds Raised through Rights Issue
November 24, 2025
Announcement on the Election of by the Employee Meeting
November 14, 2025
Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025
November 7, 2025
Announcement on Resolutions of the 10th Meeting of the 9th Board of Supervisors
October 24, 2025
Announcement on Outline of the 2025 Semi-annual Performance Briefing
September 19, 2025
Announcement on Release of Pledge of Partial Equity of Shareholder
September 8, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 22, 2025
Indicative Announcement on Acceptance of Applications for Drug Registration and Market Authorization
August 15, 2025
Announcement on Resolutions of the 11th Meeting of the 9th Board of Directors
July 25, 2025
Indicative Announcement on the Phase Ⅲ Clinical Trial of Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection Reaching the Primary Study Endpoint
July 21, 2025
Announcement on Implementation of Dividend Distribution for 2024
July 10, 2025
Announcement on Progress in Providing Entrusted Loans to Holding Subsidiary Jiaozuo Jianfeng
June 25, 2025
Announcement on Obtaining Notice of Approval for Clinical Trial
June 19, 2025
Announcement on Resolutions of the 2024 Annual General Meeting
June 6, 2025
Announcement on Progress in Providing Guarantee
June 5, 2025
Announcement on Obtaining Production License by Subsidiary in the Netherlands
May 29, 2025